Ebun Garner
Fortune : 367 614 $ au 30/09/2026
Fortune : 367 614 $ au 30/09/2026
Mr. Ebun S.
Garner is a Chief Legal Officer at Erasca, Inc. Mr. Garner was previously employed as an Assistant General Counsel by ACADIA Pharmaceuticals, Inc., a Secretary & Chief Legal Officer by Imbria Pharmaceuticals, Inc., an Associate General Counsel by Neurocrine Biosciences, Inc., a Secretary, Senior Vice President & General Counsel by Alphatec Holdings, Inc., a Secretary, Senior Vice President & General Counsel by Alphatec Spine, Inc., an Associate by Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, an Associate by Squadron, Ellenoff, Plesent & Sheinfeld LLP, and a Director General by Scient'x SA. He received his undergraduate degree from the University of Pennsylvania and a graduate degree from New York University School of Law.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ERASCA, INC. 0,01 % | 01/04/2026 | 25 076 ( 0,01 % ) | 367 614 $ | 30/09/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ERASCA, INC. | Conseiller Juridique Général | 01/04/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/04/2021 |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Conseiller Juridique Général | 01/07/2020 |
| NEUROCRINE BIOSCIENCES, INC. | Corporate Officer/Principal | 01/04/2019 |
| ALPHATEC HOLDINGS, INC. | Investor Relations Contact | 23/07/2012 |
Alphatec Spine, Inc.
Alphatec Spine, Inc. Medical SpecialtiesHealth Technology Designs, manufactures, and sells medical devices for surgical treatment of spine disorders | Conseiller Juridique Général | 28/02/2017 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Alphatec Holdings, Inc.
Alphatec Holdings, Inc. Medical SpecialtiesHealth Technology Operates as a holding company with interests in medical equipment and supplies | Health Technology |
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Squadron, Ellenoff, Plesent & Sheinfeld LLP
Squadron, Ellenoff, Plesent & Sheinfeld LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Scient'x SA
Scient'x SA Medical SpecialtiesHealth Technology Designs, develops and markets spinal implant devices for the lumbar, thoracic and cervical spine | Health Technology |
Alphatec Spine, Inc.
Alphatec Spine, Inc. Medical SpecialtiesHealth Technology Designs, manufactures, and sells medical devices for surgical treatment of spine disorders | Health Technology |
New York University School of Law
New York University School of Law Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Erasca, Inc.
Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national